Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Unable to recruit desired number of patients in reasonable time frame
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Kidney donors represent healthy patients and their anticipated postoperative course should be uncomplicated and brief. This study looks to optimize the perioperative pain regimen of laparoscopic donor nephrectomy patients by minimizing or eliminating narcotics from the immediate post-operative period. Current postoperative standard of care after donor nephrectomy require narcotic analgesics. While narcotics are potent pain medications, they are often associated with complications including nausea, vomiting and dysfunction of the gastrointestinal tract causing prolonged complications.
The investigators seek to evaluate a peri-operative pain regimen limiting the usage of narcotics. This incorporates a perioperative analgesic course utilizing combination of an intravenous non-steroidal anti-inflammatory drug (NSAID), intravenous acetaminophen, and intravenous ketamine. All three have been demonstrated to be effective for the control of perioperative pain while decreasing narcotics use.
Prior to surgery, participants will be consented and randomly assigned to receive the standard of care perioperative pain management using intravenous narcotics as a patient-controlled analgesia (PCA) by itself plus placebo or along with the new protocol. The study will demonstrate it the new protocol will limit or eliminate the need for narcotics as a patient-controlled dose during the postoperative period.
Upon discharge from the hospital, patients will be followed in clinic and via home questionnaires annually for 5 years to evaluate satisfaction, renal function and quality of life.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Ketamine | Experimental | Patients in this group will receive ketamine, morphine PCA and caldolor for pain control |
|
| placebo | Placebo Comparator | Patients in this group receive placebo, morphine PCA, and caldolor for pain control |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Ketamine | Drug |
| ||
| Placebo |
| Measure | Description | Time Frame |
|---|---|---|
| Length of hospital stay | length of stay after surgery | number of days immediately after the surgery |
| Measure | Description | Time Frame |
|---|---|---|
| post surgical complication rates | 30 day | |
| postoperative renal function (serum creatinine) | up to 2 years after intervention | |
| amount of narcotic pain medication use |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Frank Darras, MD | Stony Brook Medicine - Department of Urology | Principal Investigator |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D007649 | Ketamine |
| ID | Term |
|---|---|
| D003510 | Cyclohexanes |
| D003516 | Cycloparaffins |
| D006840 | Hydrocarbons, Alicyclic |
| D006844 | Hydrocarbons, Cyclic |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| starting immediately after the surgery, during the inpatient time period |
| postoperative nausea | number of patients reporting postoperative nausea during inpatient time period |
| return of bowel function (passage of flatus) | the number of days after surgery at which return of bowel function is achieved |
| date of postoperative ambulation | reported during inpatient time period |
| D006838 |
| Hydrocarbons |
| D009930 | Organic Chemicals |